Accessing Continuous Tableting Through a CDMO

Published on: 


Webinar Date/Time: Wed, Oct 11, 2023 - 11:00 am EDT | 4:00 pm GMT | 5:00 pm CEST | 8:00 am PDT

Join Hovione expert to understand the advantages of working with a CDMO when implementing continuous tableting (CT) and learn more about the technology-driven advantages of a CT-based program.

Register Free:

Event Overview:

The webinar, focused on continuous manufacturing of oral solid dosage forms, also known as continuous tableting (CT), will introduce the concept of working with a CDMO to develop and launch a CT-based program. The discussion will focus on the business case for continuous tableting in the context of working with a CDMO. Intrinsic technology-driven advantages such as higher product quality, greater supply chain flexibility, opportunity to accelerate time-to-market and ability to implement advanced process control as well as those that manifest from working with an experienced CDMO will be shared.

Key Learning Objectives:

  • Learn about important considerations when implementing Continuous Tableting – advantages and challenges.
  • Understand the advantages of working with a CDMO for a Continuous Tableting based program. This includes new products as well as batch to continuous conversions.
  • Case studies will be presented showing how big data sets generated in Continuous Tableting enable the implementation of process improvements.

Who Should Attend:

  • Individuals and organizations who are curious to learn about technology, its fundamental benefits and challenges.
  • Current and aspiring practitioners of the technology who are interested about the implementation of Continuous Tableting at a CDMO.


Sarang Oka, PhD
Production Senior Manager, Drug Product Continuous Manufacturing

Dr. Sarang Oka is a Senior Manager at Hovione where he heads the technical services group for Hovione’s continuous drug product manufacturing installation (CT501) in East Windsor, New Jersey, overseeing three technical functions, namely PAT, Process Development and Investigations. In his prior role at Hovione, Dr. Oka was responsible for manufacturing operations in addition to the aforementioned functions, where he successfully led the validation and tech transfer of a commercial program from one of Hovione’s partners to CT501. The program received approval from the US FDA and Dr. Oka was the technical lead for the area during the associated PAI(s). Dr. Oka started his career at Hovione as a process development engineer where he supported the installation and qualification of CT501. Dr. Oka received his PhD in Chemical Engineering from Rutgers University. His thesis focused on continuous powder mixing and granulation and examined the role of continuous manufacturing in enabling direct compression of otherwise directly incompressible formulations. He was part of the team at Rutgers University and NSF ERC-SOPS that helped develop Prezista®, the first FDA approval for a batch-to-continuous conversion of a drug product. Dr. Oka holds a BS in chemical engineering from Mumbai University.

Register Free: